R&D News | pharmaphorum

News

Philanthropic drive puts $140m behind strep A vaccine

A $140m fund launched by philanthropic group Coefficient Giving will try to find the first vaccine for Strep A, which kills 639,000 people a year.

News

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

News

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

Biogen, Denali pull Parkinson's drug after failed trial

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

Philanthropic drive puts $140m behind strep A vaccine

Lilly gets back in infectious disease, via three M&A deals

Arthrosi drug trial in gout delivers for new owner Sobi

Datroway is first TROP2 drug for frontline breast cancer

Late-breakers to look out for at ASCO 2026

Biogen, Denali pull Parkinson's drug after failed trial

On GDF-15 neutralisation and cachexia, with CatalYm

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks